Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Full Mouth Ultrasonic Debridement Carried Out With Either Piezoelectric or Magnetostrictive Device

NCT06934291 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2025-03-31
Last updated
2025-09-10

Condition(s) studied

Periodontitis, Adult

Investigational drug(s) / intervention(s)

Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon)Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply)

Full-mouth ultrasonic debridement with piezoelectric device (EMS, mini piezon): the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal

Full-mouth ultrasonic debridement with magnetostrictive device (Cavitron Select, Dentsply): the use of ultrasonic oscillating tips allows supragingival and subgingival biofilm and dental calculus removal

Study summary

The treatment of periodontitis requires the removal of dental biofilm through both professional mechanical plaque removal and at-home oral hygiene practices. This study aims to compare clinical and psychological outcomes following professional treatment using either piezoelectric or magnetostrictive ultrasonic devices.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * \>18 years * periodontitis of stage 1 and 2 * absence of systemic chronic disease Exclusion Criteria: * anticoagulants treatment * antibiotic treatment 3 months before the screening visit

Primary outcome measure(s)

  • Pain perception — through study completition, on average 6 months
    vas scale (0-10) for perception of pain after treatment
  • noise — through study completition, on average 6 months
    vas scale (0-10) for perception of noise after treatment
  • vibration — through study completition, on average 6 months
    vas scale (0-10) for perception of vibration after treatment

Trial sites (1)

FacilityCityRegionStatus
AOUS Siena SI Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06934291 on ClinicalTrials.gov ↗ ← All trials in Italy